登录 注册 会员服务 联系我们

The renaissance of polypharmacology in the development of anti-cancer therapeutics: Inhibition of the “Triad of Death” in cancer by Di-2-pyridylketone thiosemicarbazones

  • Published:2015-10 Issue: Volume:100 Page:255-260
  • ISSN:1043-6618
  • Container-title:Pharmacological Research
  • language:en
  • Short-container-title:Pharmacological Research

Author:

Jansson Patric J.,Kalinowski Danuta S.,Lane Darius J.R.,Kovacevic Zaklina,Seebacher Nicole A.,Fouani Leyla,Sahni Sumit,Merlot Angelica M.,Richardson Des R.

Funder

Cancer Institute New South Wales

Prostate Cancer Foundation of Australia

National Health and Medical Research Council of Australia

Sydney Medical School Foundation

AMP Foundation

Sydney Medical School

CINSW

Publisher

Elsevier BV

Subject

Pharmacology

Reference83 articles.

1. Polypharmacology drug discovery for the future;Reddy;Expert. Rev. Clin. Pharmacol.,2013

2. Compound promiscuity: what can we learn from current data?;Hu;Drug Discov. Today,2013

3. Clonal evolution in cancer;Greaves;Nature,2012

4. The emerging field of chemo- and pharmacoproteomics;Hess;Proteom. Clin. Appl.,2013

5. Network pharmacology: the next paradigm in drug discovery;Hopkins;Nat. Chem. Biol.,2008
同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3